Sirolimus for Injection (Albumin-bound)
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Sirolimus for Injection (Albumin-bound) is one of 69 small molecule programs targeting PEComa. It is currently in Phase 3.
4
Indications
7
Total Trials
4
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Sirolimus for Injection (Albumin-bound)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Paracetamol
GSKPreclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Advanced Solid Tumors2 trials
Breast Cancer2 trials
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Active, not recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT06957379·78 enrolledPEComa1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details